会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • Chorionic somatomammotropin hormone splice variants
    • 绒毛膜促生长激素拼接变体
    • US20070032416A1
    • 2007-02-08
    • US10540179
    • 2003-12-22
    • Tania RodriguesRichard FaganChristopher PhelpsMelanie YorkeMariastella De Tiani
    • Tania RodriguesRichard FaganChristopher PhelpsMelanie YorkeMariastella De Tiani
    • A61K38/22A61K48/00C07K14/61C07K16/26
    • C07K14/57518
    • The invention is based on the discovery that INSP100 is a splice variant of human chorionic somatomammotropin hormone 2 (HCS-B; Q14407) and that INSP104 is a splice variant of human chorionic somatomammotropin hormone 1 (hCS-A;P01243). The invention relates to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention, and treatment of disease. This invention relates to novel proteins, termed INSP100 and INSP104, herein identified as novel splice variants of human Chorionic somatomammotropin hormone 2 (hCS-B; Q14407) and human Chorionic somatomammotropin hormone 1 (hCS-A; P01243) respectively and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease. The variants have an altered A-B loop and are therefore predicted to possess altered receptor binding properties. All publications, patents and patent applications cited herein are incorporated in full by reference.
    • 本发明基于以下发现:INSP100是人绒毛膜促生长激素激素2(HCS-B; Q14407)的剪接变体,INSP104是人绒毛膜促生长激素1(hCS-A; P01243)的剪接变体。 本发明涉及来自编码基因的这些蛋白质和核酸序列在疾病的诊断,预防和治疗中的用途。 本发明涉及分别命名为INSP 100和INSP 104的新型蛋白质,其分别被鉴定为人绒毛膜促生长激素激素2(hCS-B; Q14407)和人绒毛膜促生长激素1(hCS-A; P 01243)的新型剪接变体, 使用这些蛋白质和核酸序列从编码基因中诊断,预防和治疗疾病。 变体具有改变的A-B环,因此预测具有改变的受体结合性质。 本文引用的所有出版物,专利和专利申请通过引用全部并入。